0000000000848495

AUTHOR

Ashkan Shoamanesh

showing 2 related works from this author

Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials.

2021

Abstract Aims  The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation. Methods and results  We searched MEDLINE, Embase, and CENTRAL from inception until September 2020. From 5446 citations, we selected randomized trials allocating patients with AF to antiplatelet therapy vs. control. We applied random-effects models for meta-analysis and assessed potential effect modification with background anticoagulation use. Eighteen trials including 21 518 participants met our prespecified eligibility criteria. In 10 studies without background anticoagulation, anti…

medicine.medical_specialtyMEDLINEMyocardial InfarctionHemorrhage030204 cardiovascular system & hematologylaw.inventionBrain Ischemia03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAtrial FibrillationMedicineHumansPharmacology (medical)030212 general & internal medicineMyocardial infarctionStrokeRandomized Controlled Trials as TopicAspirinbusiness.industryAnticoagulantsAtrial fibrillationmedicine.diseaseConfidence interval3. Good healthStrokeRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct